Founding offer · lifetime membership for a single £24, exclusive to our first members · closes 20 June Claim your place →
Global Research Partnerships £24 Lifetime Log inCreate free account

Funded Projects › FP7

CASCADE · Cultivated Adult Stem Cells as Alternative for Damaged tissue

FP7Status: CLOSED1 January 200931 December 2011EU funding €2,979,667

Rapid progress in stem cell research pave the way for the development and use of new cell therapy products in regenerative medicine. The objective of CASCADE is to provide the European Community with unique expertise which focuses on the GMP production of mesenchymal stem cells (MSC) and their use in treating skin and corneal wounds, so that quality and safety criteria are paramount and match therapeutic expectations. Commencing with known procedures, CASCADE will develop innovative technologies based on the expertise of its partners. Among our research themes, the specific issue of multiple recipients and universal donors will be investigated. To this end, human MSC will be derived from 4 tissues, bone marrow, fat tissue, cord blood and amniotic membrane, according to good manufacturing practice (GMP). Phenotypic identity of GMP produced MSC, their genetic status and their potential for transformation will constitute the basis for establishing standards for controlling cell production. The efficacy of GMP produced MSC will be tested in in vitro and in vivo models, and the immunological consequences of their use will be studied. Moreover, during the whole CASCADE initiative, ethical and legal issues raised as a result of MSC therapies will be considered. Direct collaboration with two clinical networks will allow CASCADE to finely tune production specifications, and define optimal clinical protocols for these MSC-based cellular therapies. CASCADE will therefore gather together leading European cell therapy laboratories with unrivalled expertise in the production of therapeutic cells and in MSC biology, four SMEs with specific know-how in GMP production of cells and two clinical networks in dermatology and ophthalmology. The outcome will be a consortium that encompasses all the technologies and skills required to efficiently develop innovative technologies for the production of clinical grade MSC and to translate this production into a cell drug to repair wounds.

Consortium · 16 organisations

coordinator

ETABLISSEMENT FRANCAIS DU SANG

FR · €430,000

participant

UNIVERSITA DEGLI STUDI DI VERONA

IT · €152,800

participant

INSTITUT NATIONAL DE LA SANTE ET DE LA RECHERCHE MEDICALE

FR · €243,725

participant

THE UNIVERSITY OF SHEFFIELD

UK · €80,000

participant

UNIVERSITAET ULM

DE · €142,798

participant

UNIVERSITATEA DE MEDICINA SI FARMACIE VICTOR BABES TIMISOARA

RO · €132,000

participant

ALCIMED

FR · €199,861

participant

FONDAZIONE IRCCS CA' GRANDA - OSPEDALE MAGGIORE POLICLINICO

IT · €204,578

participant

DRK-BLUTSPENDEDIENST BADEN-WURTTEMBERG-HESSEN GGMBH

DE · €599,414

participant

ORGANES TISSUS REGENERATION REPARATION REMPLACEMENT

FR · €74,999

participant

ABCELL-BIO Sarl

FR · €135,000

participant

UNIVERSITATSKLINIKUM HEIDELBERG

DE · €83,000

participant

THE CHANCELLOR, MASTERS AND SCHOLARS OF THE UNIVERSITY OF OXFORD

UK · €143,000

participant

BIOTRACK SRL

IT · €120,249

participant

CENTRE NATIONAL DE LA RECHERCHE SCIENTIFIQUE CNRS

FR · €115,243

participant

UNIVERSITAT DES SAARLANDES

DE · €123,000

Research fields

View the official record on CORDIS →

← Find collaborators and more funded projects

Source: CORDIS, Publications Office of the European Union. Global Research Partnerships surfaces open EU research data to help you find collaborators; we are not affiliated with the European Union.